Last reviewed · How we verify
NCT00669045
An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)
trial in Acute Myocardial Infarction in 253,668 participants. Completed in 31 March 2006.
31 March 2006
Quick facts
| Lead sponsor | Genentech, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 253,668 |
| Start date | 1 September 2000 |
| Primary completion | 31 March 2006 |
| Estimated completion | 31 March 2006 |
Conditions studied
- Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
Sponsor
Genentech, Inc. — full company profile →
Who can join
Eligibility, any sex, with Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The POST study comprised patients whose data were entered into the NRMI 4 and 5 databases. NRMI is a prospective, observational study of patients presenting with AMI in the United States. NRMI was launched in 1990 and to date has enrolled more than 2.5 million AMI patients. More than 1,700 hospitals have participated in NRMI during the last 16 years. The NRMI 4 and 5 substudies were sponsored by Genentech and collected data on approximately 160,000 AMI patients (both ST elevation and non-ST-elevation MI) hospitalized in the United States each year. This corresponds to approximately 18% of the AMI patients in the United States.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00669045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myocardial Infarction
Currently open trials in the same condition.
- NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
- NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
- NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
- NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
- NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting
Other Genentech, Inc. trials
Trials by the same sponsor.
- NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
- NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00669045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
- Last refreshed: 15 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00669045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing